An Updated Review of Cardiovascular Events in Giant Cell Arteritis
- PMID: 35207277
- PMCID: PMC8878095
- DOI: 10.3390/jcm11041005
An Updated Review of Cardiovascular Events in Giant Cell Arteritis
Abstract
Giant cell arteritis (GCA) is a systemic vasculitis with a direct and indirect increased risk of acute and chronic vascular events, affecting large and medium vessels, and responsible for most of the morbidity and mortality of this disease. We aimed in this review to provide an updated synthesis of knowledge regarding cardiovascular events observed in GCA. By definition, GCA patients are over 50 and often over 70 years old, and subsequently also present age-related cardiovascular risk factors. In addition, the systemic and vascular inflammation as well as glucocorticoids (GC) probably contribute to an accelerated atherosclerosis and to vascular changes leading to arterial stenoses and aortic dilations and/or dissections. GCA-related ischemic complications, especially ophthalmologic events, stroke or myocardial infarcts are mostly observed within the first months after the diagnosis, being mainly linked to the vasculitic process. Conversely, aortic complications, including dilations or dissections, generally occur several months or years after the diagnosis, mainly in patients with large-vessel vasculitis. In these patients, other factors such as atherosclerosis, GC-related endothelial damage and vascular wall remodeling/healing probably contribute to the vascular events. GCA management includes the detection and treatment of these previous and newly induced cardiovascular risk factors. Hence, the use of cardiovascular treatments (e.g., aspirin, anticoagulation, statins, anti-hypertensive treatments) should be evaluated individually. Aortic structural changes require regular morphologic evaluations, especially in patients with previous aortitis. The initial or secondary addition of immunosuppressants, especially tocilizumab, an anti-IL-6 receptor antibody, is discussed in patients with GCA-related cardiovascular complications and, more consensually, to limit GC-mediated comorbidities.
Keywords: aortic dilation; aortic dissection; cardiovascular event; giant cell arteritis; large vessel vasculitis; myocardial infarction; peripheral artery disease; stroke.
Conflict of interest statement
de Boysson received speaker/consulting fees from Roche-Chugai.
Similar articles
-
Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis.Ther Adv Musculoskelet Dis. 2021 Jun 27;13:1759720X211006967. doi: 10.1177/1759720X211006967. eCollection 2021. Ther Adv Musculoskelet Dis. 2021. PMID: 34249150 Free PMC article.
-
Prognosis and monitoring of giant cell arteritis and associated complications.Expert Rev Clin Immunol. 2018 May;14(5):379-388. doi: 10.1080/1744666X.2018.1467758. Epub 2018 Apr 26. Expert Rev Clin Immunol. 2018. PMID: 29676201 Review.
-
Cardiovascular lesions in giant cell arteritis.Reumatologia. 2022;60(6):399-407. doi: 10.5114/reum.2022.123670. Epub 2022 Dec 30. Reumatologia. 2022. PMID: 36683841 Free PMC article. Review.
-
Preventive effect of beta-blockers in the development of aortic dilation in giant cell arteritis-related aortitis.Semin Arthritis Rheum. 2022 Dec;57:152117. doi: 10.1016/j.semarthrit.2022.152117. Epub 2022 Oct 24. Semin Arthritis Rheum. 2022. PMID: 36335685
-
[Long-term complications, monitoring and interventional treatment of large vessel vasculitis].Z Rheumatol. 2020 Aug;79(6):523-531. doi: 10.1007/s00393-020-00807-1. Z Rheumatol. 2020. PMID: 32430565 Review. German.
Cited by
-
Risk Factors and Pharmacological Interventions Impacting Cerebrovascular Ischemic Events in Giant Cell Arteritis: A Narrative Review.Immun Inflamm Dis. 2025 Jan;13(1):e70122. doi: 10.1002/iid3.70122. Immun Inflamm Dis. 2025. PMID: 39817601 Free PMC article. Review.
-
The Meteoritics Trial: efficacy of methotrexate after remission-induction with tocilizumab and glucocorticoids in giant cell arteritis-study protocol for a randomized, double-blind, placebo-controlled, parallel-group phase II study.Trials. 2024 Jan 15;25(1):56. doi: 10.1186/s13063-024-07905-4. Trials. 2024. PMID: 38225579 Free PMC article.
-
Exploring Cardiovascular Manifestations in Vasculitides: An In-Depth Review.Cureus. 2023 Aug 30;15(8):e44417. doi: 10.7759/cureus.44417. eCollection 2023 Aug. Cureus. 2023. PMID: 37791229 Free PMC article. Review.
-
Correlation and Risk Assessment of Inflammation-Based Parameters on Cardiovascular Parameters and Clinical Events in Giant Cell Arteritis: A Retrospective Study.Int J Mol Sci. 2025 Jul 21;26(14):7016. doi: 10.3390/ijms26147016. Int J Mol Sci. 2025. PMID: 40725261 Free PMC article.
-
Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis.RMD Open. 2024 Dec 10;10(4):e004694. doi: 10.1136/rmdopen-2024-004694. RMD Open. 2024. PMID: 39658053 Free PMC article.
References
-
- de Boysson H., Liozon E., Ly K.H., Dumont A., Delmas C., Aouba A. The different clinical patterns of giant cell arteritis. Clin. Exp. Rheumatol. 2019;37((Suppl. 117)):57–60. - PubMed
-
- Agard C., Barrier J.H., Dupas B., Ponge T., Mahr A., Fradet G., Chevalet P., Masseau A., Batard E., Pottier P., et al. Aortic involvement in recent-onset giant cell (temporal) arteritis: A case-control prospective study using helical aortic computed tomodensitometric scan. Arthritis Rheum. 2008;59:670–676. doi: 10.1002/art.23577. - DOI - PubMed
-
- Prieto-Gonzalez S., Depetris M., Garcia-Martinez A., Espigol-Frigole G., Tavera-Bahillo I., Corbera-Bellata M., Planas-Rigol E., Alba M.A., Hernandez-Rodriguez J., Grau J.M., et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: A prospective, case-control study. Ann. Rheum. Dis. 2014;73:1388–1392. doi: 10.1136/annrheumdis-2013-204572. - DOI - PubMed
-
- Bienvenu B., Ly K.H., Lambert M., Agard C., Andre M., Benhamou Y., Bonnotte B., de Boysson H., Espitia O., Fau G., et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA) Rev. Med. Interne. 2016;37:154–165. doi: 10.1016/j.revmed.2015.12.015. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous